
|Articles|March 1, 2020
- Pharmaceutical Executive-03-01-2020
- Volume 40
- Issue 3
Pharmaceutical Executive, March 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
The Multichannel Reach: Balancing the Local and Global Voicealmost 6 years ago
Market Access: From Being to Becomingalmost 6 years ago
Consider Data Before It’s a Problemalmost 6 years ago
Multichannel Marketing: Integrating Omnichannelalmost 6 years ago
Feds Target Biosimilar Anticompetitive Practicesalmost 6 years ago
Blood Feud Divides Europe Over Plasma Shortfallsalmost 6 years ago
Social Media’s Influence in Messaging Mixalmost 6 years ago
Habib Bennaceur: Following the Sciencealmost 6 years ago
A Bad Deal with Data?almost 6 years ago
Country Report: United Arab EmiratesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5




